Pneumococcal vaccine conjugate 10-valent - Panacea Biotech

Drug Profile

Pneumococcal vaccine conjugate 10-valent - Panacea Biotech

Alternative Names: 10-Valent pneumococcal polysaccharide conjugate vaccine - Panacea Biotech; Nucovac; Pneumococcal 10-valent conjugate vaccine (adsorbed) - Panacea Biotech

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator Panacea Biotec
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pneumococcal infections

Most Recent Events

  • 20 Apr 2016 Phase-I/II development for Pneumococcal infections (In adults, Prevention) is ongoing in India
  • 01 Jun 2013 Phase-I/II clinical trials in Pneumococcal infections (prevention in volunteers) in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top